TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
NASDAQ · ABCL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
AbCellera Biologics Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.18. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow AbCellera Biologics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.15+11.76% vs estimate | $4.24M-42.06% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.11+26.67% vs estimate | $5.05M-33.37% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | -$0.17-21.43% vs estimate | $6.51M-14.15% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $13.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
CA$12.41+CA$2.74 (+28.34%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.9% below the high.
$17.21-$0.15 (-0.86%)
Aurinia Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.6% below the high.
$12.10+$0.22 (+1.85%)
Absci Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.55% below the high.
$15.77+$0.39 (+2.54%)
Generate Biomedicines, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.44% below the high.
$12.74-$0.58 (-4.35%)
Ginkgo Bioworks Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.08% below the high.
